Session: LBA02: Late-Breaking Abstracts II - Cancer
LBA02-01: Biochemical recurrence of localized prostate cancer originating from the transition versus peripheral zone: a systematic review and meta-analysis
Introduction: The influence of zonal origin of localized prostate cancer (PC) on biochemical recurrence (BCR) is still controversial. We performed a meta-analysis of published articles to compare BCR of localized PC originating from the transition versus peripheral zone. Methods: Systematic research of Medline, Embase, Scopus, Web of Science, and the Cochrane Library was performed to identify all trials on BCR of localized PC originating from transition and peripheral zone. The incidences of BCR were pooled with a fixed or random effect model and reported as Risk Ratio (RR), and 95% Confidence Intervals (CI). Study heterogeneity was assessed using the I2 value. Substantial heterogeneity was defined as an I2 value >50%. Subgroup analysis was performed according to follow-up time, prostate-specific antigen (PSA) levels, Newcastle–Ottawa Scale (NOS) score, and whether a multivariate or univariate Cox regression model was used. Results: A total of 16 cohorts with 19,365 patients were included. Overall, PC originating from transition zone was associated with a lower risk of BCR (RR, 0.79, 95%CI; 0.69-0.92, I2, 76.8%). This association was consistent in subgroup analyses of studies with median follow-up time =60 months (RR, 0.65; 95%CI, 0.48 to 0.88, I2 56.8%), median PSA <10ng/ml (RR, 0.68; 95%CI, 0.49 to 0.94, I2 84.4%), median PSA >10ng/ml (RR, 0.91; 95%CI, 0.88 to 0.94, I2 14.8%), NOS score =8 (RR, 0.70; 95%CI, 0.62 to 0.80, I2 32.4%), and studies using a multivariate regression model (RR, 0.57; 95%CI, 0.48 to 0.69, I2 23%). Conclusions: This meta-analysis showed a decreased incidence of BCR of localized PC originating from transition zone compared to peripheral zone, especially in studies using a multivariate regression model. Therefore, it was supported that PC originating from transition zone might be a different clinical entity with a significantly lower risk of BCR. SOURCE OF Funding: National High Level Hospital Clinical Research Funding of Peking Union Medical College Hospital [2022-PUMCH-A-063, 2022-PUMCH-B-009]
